Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Products In Brief

This article was originally published in The Tan Sheet

Executive Summary

DSM's resveratrol raises the bar: Rancho Santa Fe, Calif.-based ResVez Inc. launches Winetime Bar, a chocolate nutrition bar with "as much resveratrol as 50 glasses of red wine," the company says Dec. 1. Winetime contains DSM Nutritional Products' resVida trans-resveratrol ingredient, which ResVez says "comes with the most extensive scientific and safety substantiation in the marketplace." Winetime, also containing super fruits such as noni and mangosteen, sells through ResVez's Web site at $29.90 for 10 bars or $89.70 for 40 bars, plus shipping

You may also be interested in...



Glaxo Shifts Rx Resveratrol Focus But Nutritional Interest Still Strong

GlaxoSmithKline's decision to abandon its pharmaceutical research program on resveratrol leaves the red wine extract exclusively to the nutritionals industry.

Glaxo Shifts Rx Resveratrol Focus But Nutritional Interest Still Strong

GlaxoSmithKline's decision to abandon its pharmaceutical research program on resveratrol leaves the red wine extract exclusively to the nutritionals industry.

Glaxo Shifts Rx Resveratrol Focus But Nutritional Interest Still Strong

GlaxoSmithKline's decision to abandon its pharmaceutical research program on resveratrol leaves the red wine extract exclusively to the nutritionals industry.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS103640

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel